Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

Abstract

Backgrounds To assess the changes in individual retinal layer thickness and visual function associated with gains in visual acuity after an intravitreal conbercept injection in the diabetic macular edema (DME) on spectral domain optical coherence tomography (SD-OCT) and microperimetry during 1-year follow-up. Methods Retrospective observational study. Twenty patients with clinically significant DME in the study eye were imaged by SD-OCT every 3 months and MP1 microperimeter in the third month while receiving anti-vascular endothelial growth factor (VEGF) (conbercept) treatment. In each patient, seven retinal layers were segmented in 98 scans covering a 6 mm × 6 mm area of the macula at baseline and during 1 year of treatment. An automatic, full-threshold microperimetry of the central field (10° × 10°, 40 stimulated points) with the MP1 microperimeter. Thickness and microperimetry changes were quantitatively measured and evaluated for their correlation with increases in visual acuity. Results Although thicknesses of the inner nuclear layer (INL) and the outer nuclear layer (ONL) were reduced the most after treatment ( p < 0.05), decreases of the ganglion cell layer (GCL) ( r = 0.591, p = 0.006) and inner plexiform layer (IPL) ( r = 0.663, p = 0.001) in central subfield area was associated with best-corrected visual acuity (BCVA) gain, and had the best estimation of BCVA gain (adjust R 2 = 0.544). Mean macular sensitivity in the central subfield was also well correlated with BCVA gain ( r = 0.531, p = 0.016). Conclusions Neural recovery occurred after the resolution of edema during conbercept treatment, due to the decreases in GCL and IPL associating with gains in vision and improved microperimetry. Electronic supplementary material The online version of this article (10.1186/s12886-019-1131-0) contains supplementary material, which is available to authorized users.

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review

“…The cumulative mean number of injections was 6 (5 studies with 5 treatment arms). Two studies each reported the mean number of injections for conbercept 1 dose at baseline (1q4w) followed by PRN regimen (5.6 46 and 6.8 45 ) and conbercept 3q4w followed by PRN regimen (6.6 36 and 6.6 47 ) ( Figure S6 ).…”

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

“…Triamcinolone acetonide has a strong antiallergic effect and lasting for a long time. After intravitreal injection, it can block the proliferation of endothelial cells and angiogenesis, achieving the effect of treating fundus vascular diseases and the best-corrected visual acuity of patients [ 24 , 25 ]. In addition, its action inhibits the production of prostaglandins, downregulates VEGF expression, and has a synergistic effect with conbercept [ 26 ].…”

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

“…15,16 Conbercept (KH902; Chengdu Kanghong Biotechnology Co., Ltd., Sichuan, China), a new anti-VEGF reagent, has been developed and used in clinical treatment. 17 Previous studies have shown that conbercept can improve a variety of clinical symptoms, such as best corrected visual acuity (BCVA), central foveal thickness (CFT), and choroidal neovascularization area. 18 Conbercept has been used in the treatment of diabetic macular edema, 17 wet age-related macular degeneration, 19 chronic central serous chorioretinopathy, 20 and proliferative diabetic retinopathy.…”